Floatz logo

Pertuzumab

Rectum Adenocarcinoma

SWOG Cancer Research Networkmonoclonal_antibodyPhase 2Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

40 Active assets in the Rectum Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Fluorouracilum
Merck Sharp & Dohme LLC
Phase 3BBB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BBB
Xaliplatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Cetuximab
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Trifluridine
Sir Run Run Shaw Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

Pertuzumab is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 3
75 / 100
View asset →
inflammatory breast carcinomaActive
BBB
Indicative · Phase 3
72 / 100
View asset →
breast cancerActive
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →